Previous Section
Drug Therapy
8. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
- Author
- Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G;
- Institution
- Cardiac Rehabilitation Unit, Istituti Clinici di Perfezionamento, Milan, Italy. cardriab@icp.mi.it
- Journal
- N Engl J Med. 2007 Jan 4;356(1):39-46.
- Abstract URL
- Click here to view abstract
9. Rivastigmine and Parkinson dementia complex.
- Author
- Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G;
- Institution
- University of Trieste, Clinical Neurology, Department of Internal Medicine and Clinical Neurology, Ospedale di Cattinara, Strada di Fiume, 447 34149 Trieste, Italy. moretti@univ.trieste.it
- Journal
- Expert Opin Pharmacother. 2007 Apr;8(6):817-29.
- Abstract URL
- Click here to view abstract
10. When Should Levodopa Therapy be Initiated in Patients with Parkinson's Disease?
- Author
- Halkias IA; Haq I; Huang Z; Fernandez HH;
- Institution
- Department of Neurology, University of Florida, Gainesville, Florida, USA.
- Journal
- Drugs Aging. 2007;24(4):261-73.
- Abstract URL
- Click here to view abstract
11. Dopamine agonists and the risk of cardiac-valve regurgitation.
- Author
- Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E;
- Institution
- Department of Clinical Pharmacology, Charite Campus Mitte, Charite-Universitatsmedizin Berlin, Berlin.
- Journal
- N Engl J Med. 2007 Jan 4;356(1):29-38.
- Abstract URL
- Click here to view abstract
Next: Clinical Trials
